Company / Revenue
Neurocrine Biosciences Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$2.9B
FY2025
5-year range
$1.0B / $2.9B
FY2021-FY2025
Trend
+21.4%
vs FY2024
Sector context
#27 of 155
Health Care
What the data says
Neurocrine Biosciences's revenue of $2.9B is higher than 83% of companies in the Health Care sector (FY2025). Revenue has increased for 3 consecutive years, from $1.0B in FY2022 to $2.9B in FY2025.
Based on SEC 10-K filings.
$2.9B in FY2025 with a 5-year CAGR of +22.3%. Top quartile in the Health Care sector.
Improved from $1.9B to $2.9B over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +39.8%
- 5-Year CAGR
- +22.3%
- 10-Year CAGR
- -
Sector benchmark
Top 17% in Health CareTop 17% of 155This company $2.9B Sector average $4.5B
▼
-36.0% below sector average
Key checks
Key Insights
- Neurocrine Biosciences's revenue has grown for 3 consecutive years.
- 5-year CAGR of +22.3%, indicating consistent growth.
- In FY2025, revenue increased 21.4% year-over-year.
- Ranks #27 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.9B | +21.4% |
| FY2024 | $2.4B | +24.8% |
| FY2023 | $1.9B | +80.4% |
| FY2022 | $1.0B | -7.7% |
| FY2021 | $1.1B | +8.4% |
| FY2020 | $1.0B | +32.7% |
| FY2019 | $788.1M | +74.7% |
| FY2018 | $451.2M | - |
| FY2017 | $0 | -100.0% |
| FY2016 | $15.0M | -24.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026